FDA panel backs Astellas drug for invasive fungal infections

January 22, 2015 8:28 PM

18 0

(Reuters) - A panel of experts on Thursday voted to recommend that U.S. health regulators approve Astellas Pharma Inc's drug for the treatment of rare, often fatal invasive fungal infections that can target patients with blood cancers.

The Anti-Infective Drugs advisory committee panel voted 11-0 that the Japanese drugmaker had demonstrated sufficient safety and efficacy to support approval of the drug, isavuconazonium to treat invasive aspergillosis.

Read more

To category page